NCT00006079 is a Phase 2 clinical trial of Eflornithine in Cervical Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00006079?

NCT00006079 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00006079?

Interventions in NCT00006079: Eflornithine, Placebo.

What condition does NCT00006079 study?

NCT00006079 studies Cervical Cancer, Precancerous Condition.

Is NCT00006079 still recruiting?

NCT00006079 is currently completed. Last updated 25 October 2018.

Last reviewed 2018-10-25 · How we verify

NCT00006079

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Completed Phase 2 Last updated 25 October 2018

What this trial tests

Phase 2 trial testing Eflornithine in Cervical Cancer in 150 participants. Completed in 27 April 2004.

Timeline

19 June 1998

Primary endpoint
27 April 2004

27 April 2004

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	triple
Primary purpose	prevention
Enrollment	150
Start date	19 June 1998
Primary completion	27 April 2004
Estimated completion	27 April 2004
Sites	1 location across United States

Drugs / interventions tested

Eflornithine (EFLORNITHINE) — full drug profile →
Placebo

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →
Precancerous Condition — all drugs for Precancerous Condition →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, female only, with Cervical Cancer or Precancerous Condition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of eflornithine may be an effective way to prevent the recurrence of or further development of cervical cancer. PURPOSE: Randomized phase II trial to determine the effectiveness of eflornithine in preventing cervical cancer in patients who have cervical intraepithelial neoplasia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Eflornithine

Trials testing the same drug.

NCT07468136 — Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas · Phase 1, PHASE2 · not yet recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
NCT05717153 — Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma · EARLY_PHASE1 · recruiting
NCT04301843 — Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma · Phase 2 · recruiting
NCT02794428 — Chemoprevention of Gastric Carcinogenesis · Phase 2 · completed

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00006079 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 25 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00006079.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing